|
| Interactions: | AcenocoumarolAdverse Effect: Increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Flunarizine and Acenocoumarol should be monitored for excessive bleeding, especially from the gastrointestinal tract.
Amiodarone Adverse Effect: Atrioventricular block and slowing of sinus rate
Clinical Management: Concurrent use of amiodarone and Flunarizine should be avoided in patients with sick sinus syndrome or partial AV (atrioventricular) block.
Atenolol Adverse Effect: hypotension, bradycardia, and AV conduction disturbances
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure or bradyarrhythmias.
BetaxololAdverse Effect: Hypotension, bradycardia, and AV conduction disturbances
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure or bradyarrhythmias.
BisoprololAdverse Effect: hypotension, bradycardia, and AV conduction disturbances
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure or bradyarrhythmias.
Carbamazepine Adverse Effect: Increased carbamazepine serum levels and possible toxicity (ataxia, nystagmus, diplopia, headache, vomiting, apnea, seizures, coma)
Clinical Management: Continue routine monitoring of carbamazepine serum levels. Some dose adjustment may be needed if both clinical symptoms and laboratory findings suggest carbamazepine toxicity.
CarvedilolAdverse Effect: Hypotension, bradycardia, and AV conduction disturbances
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure or bradyarrhythmias.
CelecoxibAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
CeliprololAdverse Effect: hypotension, bradycardia, and AV conduction disturbances
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure or bradyarrhythmias.
EsmololAdverse Effect: Hypotension, bradycardia, and AV conduction disturbances
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure or bradyarrhythmias.
FlurbiprofenAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ibuprofen Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
IndomethacinAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ketoprofen Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ketorolac Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
LabetalolAdverse Effect: Hypotension, bradycardia, and AV conduction disturbances
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure or bradyarrhythmias.
Levobunolol Adverse Effect: Hypotension, bradycardia, and AV conduction disturbances
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure or bradyarrhythmias.
Mefenamic Acid Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
MeloxicamAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
MetoprololAdverse Effect: hypotension, bradycardia, and AV conduction disturbances
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure or bradyarrhythmias.
Nabumetone Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Naproxen Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
NimesulideAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
OxprenololAdverse Effect: hypotension, bradycardia, and AV conduction disturbances
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure or bradyarrhythmias.
OxyphenbutazoneAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
ParacetamolAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
PhenacetinAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
PhenindioneAdverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Flunarizine and Phenindione should be monitored for excessive bleeding, especially from the gastrointestinal tract.
PhenylbutazoneAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
PindololAdverse Effect: hypotension, bradycardia, and AV conduction disturbances
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure or bradyarrhythmias.
Piroxicam Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
PropranololAdverse Effect: hypotension, bradycardia, and AV conduction disturbances
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure or bradyarrhythmias.
RifampicinAdverse Effect: Decreased flunarizine efficacy
Sotalol Adverse Effect: Hypotension, bradycardia, and AV conduction disturbances
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure or bradyarrhythmias.
Tenoxicam Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Timolol Adverse Effect: Hypotension, bradycardia, and AV conduction disturbances
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure or bradyarrhythmias.
WarfarinAdverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Flunarizine and Warfarin should be monitored for excessive bleeding, especially from the gastrointestinal tract. |
|
|